{"id":"W4399481268","doi":"10.1200/jco.2024.42.16_suppl.7055","title":"A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Manitoba; Jewish General Hospital; CancerCare Manitoba","funders":"","keywords":"Medicine; Pembrolizumab; Refractory (planetary science); Classical Hodgkin lymphoma; Oncology; Lymphoma; Internal medicine; Cancer research; Immunotherapy; Hodgkin lymphoma; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003405039,0.0009428918,0.001622198,0.0006699347,0.0002754353,0.001088909,0.0006717684,0.0007875771,0.002536272],"category_scores_gemma":[0.001957658,0.000548793,0.002320795,0.0007413745,0.0003762649,0.0007990295,0.0003653037,0.001300151,0.0005389307],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001099295,"about_ca_system_score_gemma":0.001437944,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00182896,"about_ca_topic_score_gemma":0.005566434,"domain_scores_codex":[0.9991056,0.0004323879,0.00006598867,0.0001577989,0.0001412969,0.00009695434],"domain_scores_gemma":[0.998845,0.0002407814,0.0003961084,0.000101057,0.0001238873,0.0002931205],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5437878,0.01409158,0.1198702,0.004831799,0.03422615,0.000925697,0.0005245226,0.003419939,0.03660537,0.0003732651,0.01182421,0.2295195],"study_design_scores_gemma":[0.4232405,0.1798917,0.316059,0.0005468175,0.03654555,0.002727759,0.0002431362,0.002778013,0.004731562,0.0006005082,0.03246051,0.00017498],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9643049,0.02003106,0.001197589,0.0005828255,0.0001489194,0.003349569,0.007545139,0.0001370263,0.002703003],"genre_scores_gemma":[0.9693211,0.009967855,0.002579895,0.00144226,0.0001608295,0.001873758,0.01294382,0.00005342093,0.001656997],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003405039,"threshold_uncertainty_score":0.01800776,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1006543657498181,"score_gpt":0.4814330227714067,"score_spread":0.3807786570215886,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}